Imperial College London
Portrait Picture

Professor Thanos Athanasiou MD PhD MBA FECTS FRCS

Faculty of Medicine, Department of Surgery & Cancer

Professor of Cardiovascular Sciences
 
 
 
//

Contact

 

t.athanasiou

 
 
//

Location

 

1022Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fergadi:2022:10.1007/s00261-021-03334-y,
author = {Fergadi, MP and Magouliotis, DE and Rountas, C and Vlychou, M and Athanasiou, T and Symeonidis, D and Pappa, PA and Zacharoulis, D},
doi = {10.1007/s00261-021-03334-y},
journal = {Abdom Radiol (NY)},
pages = {254--264},
title = {A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer.},
url = {http://dx.doi.org/10.1007/s00261-021-03334-y},
volume = {47},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: This study aimed to evaluate the outcomes of high-intensity focused ultrasound (HIFU) on patients with advanced pancreatic cancer. METHODS: A literature search was performed in PubMed, Scopus and Cochrane databases, in accordance with the PRISMA guidelines. The Odds Ratio, Weighted Mean Difference, and 95% Confidence Interval were evaluated by means of the Random-Effects model. RESULTS: Nineteen articles met the inclusion criteria, incorporating 939 patients. This study reveals that patients in the HIFU group presented increased median overall survival (OS), along with higher OS at 6 and 12 months after treatment compared with the control group (p < 0.05). Furthermore, patients treated with HIFU in conjunction with chemotherapy presented reduced levels of pain (p < 0.05) compared to the traditional treatment group. In addition, HIFU contributed to significant tumor responsiveness, in terms of CA19-9 reduction (p < 0.05). Finally, HIFU was a considerably safe treatment modality with a low incidence of complications. CONCLUSION: These outcomes suggest that HIFU is a feasible and safe treatment modality for patients with advanced pancreatic cancer and provides enhanced outcomes regarding survival and quality of life. Given the lack of a significant number of randomized clinical trials, this meta-analysis represents the best currently available evidence. New randomized trials assessing HIFU are necessary to further evaluate their outcomes.
AU  - Fergadi,MP
AU  - Magouliotis,DE
AU  - Rountas,C
AU  - Vlychou,M
AU  - Athanasiou,T
AU  - Symeonidis,D
AU  - Pappa,PA
AU  - Zacharoulis,D
DO  - 10.1007/s00261-021-03334-y
EP  - 264
PY  - 2022///
SP  - 254
TI  - A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer.
T2  - Abdom Radiol (NY)
UR  - http://dx.doi.org/10.1007/s00261-021-03334-y
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34718835
VL  - 47
ER  -
Download